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Abstract
Chronic lymphocytic leukemia (CLL) is thought to be a disease of resting lymphocytes. However, recent data suggest that
CLL cells may more closely resemble activated B cells. Using microRNA (miRNA) expression profiling of highly-enriched CLL
cells from 38 patients and 9 untransformed B cells from normal donors before acute CpG activation and 5 matched B cells
after acute CpG activation, we demonstrate an activated B cell status for CLL. Gene set enrichment analysis (GSEA) identified
statistically-significant similarities in miRNA expression between activated B cells and CLL cells including upregulation of
miR-34a, miR-155, and miR-342-3p and downregulation of miR-103, miR-181a and miR-181b. Additionally, decreased levels
of two CLL signature miRNAs miR-29c and miR-223 are associated with ZAP70
+ and IgVH unmutated status and with shorter
time to first therapy. These data indicate an activated B cell status for CLL cells and suggest that the direction of change of
individual miRNAs may predict clinical course in CLL.
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Introduction
CLL is the most common form of adult leukemia in the western
world accounting for approximately 30% of all leukemias in
Caucasians. Contrary to its earlier description as a relatively
homogeneous disease, CLL more recently has been viewed as a
heterogeneous disease with variable clinical course that correlates
with several biologic markers of prognosis [1] The most clinically
significant prognostic markers are cytogenetics determined by
fluorescence in situ hybridization (FISH) and IgVH followed by
ZAP70 status. Patients with CLL demonstrating deletion of 11q or
17p, high expression of ZAP70 or CD38, or relative absence of V
region somatic hypermutation have markers that indicate more
aggressive disease.
CLL is characterized as a disease of mature B cells. CLL cells
typically express an anergic B cell receptor (BCR) and
demonstrate dysregulated apoptotic programs. mRNA expres-
sion profiling has been used to classify CLL [2,3,4,5]. Though it
is not generally considered a disease of activated B cells, mRNA
expression profiling in one study characterized CLL cells as
similar to activated B cells [2] and in another as similar to
memory B cells [3]. In normal B cells, the nuclear translocation
of NF-kB is associated with B cell activation. Constitutive
nuclear localization of NF-AT (nuclear factor of activated T
cells) and NF-kB2/p52 characterizes CLL cells [6], suggesting
an activated B cell state. Moreover, CLL cells demonstrate
higher NF-kB DNA binding activity than untransformed B cells,
the RelA subunit of NF-kBh a sb e e ns h o w nt ob ea s s o c i a t e d
with clinical disease progression, and RelA binding activity is
inversely correlated with apoptosis in CLL cells [7]. Recently,
CLL cells were shown to express activated cell surface markers
and intracellular phenotypes [8].
CLL has also been classified by miRNA expression profiling
[9,10,11,12,13,14]. Interestingly, none of these miRNA expression
profiles for CLL are identical. Dysregulation of particular miRNAs
in some CLL signatures have been implicated in the CLL cell
apoptotic defect. For example, downregulated miR-15a and miR-
16-1 fail to repress Bcl-2 [15] and downregulated miR-29 fails to
repress Mcl-1 [16].
Using miRNA expression profiling, we identified a miRNA
signature in untransformed B cells induced soon after activation.
This activated B cell miRNA signature is also present in CLL cells
indicating an activated B cell phenotype for CLL. Our data imply
that individual miRNAs involved in B cell activation may
participate in the B cell transformation process and could be
targets for therapeutic gene silencing in CLL.
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Control B cell donor and CLL cell patient characteristics
Cells from 38 CLL patients were assessed in this study. All
patients were enrolled on a tissue banking protocol, #99-224,
prior to sample collection. This tissue banking protocol was
approved by the Dana-Farber Cancer Institute (DFCI) Institu-
tional Review Board, and informed consent was obtained from all
CLL patients prior to sample collection. These patients had white
blood counts (WBC) between 15.7610
3 and 265.6610
3 cells per
microliter of blood. 3 of the CLL patients were treated, while the
other 35 patients were untreated. Control blood samples were
from healthy donors. ZAP-70 status, IgVH mutation, and genomic
aberrations were determined as described in Methods S1. The
clinical parameters are summarized in Table S1.
Control B cell and CLL cell purification
Ten mL of heparinized peripheral blood was subjected to Ficoll-
Paque
TM PLUS (GE Healthcare, Pittsburgh, PA, USA) density
centrifugation. Control B and CLL cells were purified from
peripheral blood mononuclear cells (PBMCs) by positive selection
with CD19
+ selection beads as suggested by the manufacturer
(StemCell Technologies Inc, Vancouver, Canada), and then were
immediately used for RNA isolation or activation treatment.
Control B cell culture and activation
B cells were cultured in Iscove’s Modified Dulbecco’s Medium
(IMDM) (GIBCO, Carlsbad, CA, USA) supplemented with 10%
human AB serum (Mediatech, Inc, Herndon, VA, USA), 1%
Penicillin-Streptomycin (GIBCO, Aukland, NZ, USA), 1% HEPES
(Mediatech,Inc, Herndon, VA, USA),1%L-glutamine (Mediatech,
Inc,Manassas, VA,USA), 50 mg/mL human transferrin(Sigma, St.
Louis, MO, USA) and 5 mg/mL insulin (Sigma, St. Louis, MO,
USA). The cells were kept in a 37uC incubator with 5% CO2.
For CD40 activation, NIH-3T3 CD40L or NIH-3T3 feeder cells
were cultured to confluency and then irradiated for 9 K by Cs-
irradiator. Irradiated feeder cells were plated in 6 well plates at
2610
5 cells/mL overnight at 37uC. The cells were washed twice
gentlywith PBS and the B cellmedium was added. Purified control B
cells were co-cultured with the feeder cells at 37uC for 24 hr or 48 hr.
For BCR activation, purified control B cells were adjusted to
1610
7 cells in 0.1 M phosphate buffered saline (pH 7.2). Goat
anti-human immunoglobulin M (IgM) F(ab’)2 (Southern Biotech-
nology Associates, Birmingham, AL, USA) at 10 mg/mL was
added to untransformed B cells for 20 min. on ice. These cells
were transferred to human B cell medium and cultured for 24 hr
or 48 hr at 37uC. For other methods of activation, 5610
6 control
B cells were plated in 5 mL of medium containing lipopolysac-
charide (LPS) (0.5 ng/mL, Alexis, San Diego. CA, USA), CpG
(1 mM, Hycult Biotech, Canton, MA, USA, the sequence of the
CpG is 59 tcgtcgttttgtcgttttgtcgtt 39), or polyI:C (5 ng/mL,
Invivogen, San Diego, CA, USA) at 37uC for 24 hr or 48 hr.
For experiments involving inhibitors for the c-jun NH2-terminal
kinase (JNK) or mitogen-activated protein kinase/ERK kinase
(MEK), cells was co-cultured with the JNK inhibitor SP600125
(50 mM, A. G. Scientific, Inc., San Diego, CA, USA) or MEK
inhibitor PD98059 (50 mM Sigma, St. Louis, MO, USA) for 24 hr
before the isolation of RNA for RT-PCR assay.
FACS analysis
CLL cell purity was tested using anti-CD5-PE and anti-CD19-
FITC (BD Pharmingen, San Diego, CA, USA) antibodies. The
activation of control B cells was tested using anti-CD69-FITC,
anti-CD80-FITC or anti-CD86-FITC (BD Pharmingen, San
Diego, CA, USA). These antibodies were incubated on ice with
the B cells in the presence of PBS with 2% FBS (GIBCO,
Carlsbad, CA, USA) for approximately 30 min., the cells were
washed with PBS at 4uC for 10 min., centrifuged for 100 g at 4uC,
supernatants were aspirated. The cell pellets were re-suspended in
200 mL of PBS and analyzed by FACSCalibur (Becton Dickinson).
Total RNA preparation
Total RNA from control B or CLL cells was extracted by Trizol
method (Invitrogen, Carlsbad, CA, USA). Dried RNA pellets were
re-suspended in appropriate volumes of DEPC/ddH2O. RNA was
quantitated by O.D.260/280 using spectrophotometry DU640
(Beckman).
MiRNA expression profiling
We first profiled 435 miRNAs from 22 CLL samples and 1
control B sample by the Luminex method requiring multiple gel
extraction steps as described [17]. To expand our sample size, we
then chose 43 miRNAs which were predicted to be differentially
expressed in CLL from our previous data, 4 miRNAs from
published data, and 3 control miRNAs (listed in Table S2) for
large scale profiling with the FlexmiR miRNA labeling kit
(Luminex, Austin, TX, USA, as described [18]. In this method,
2.5 mg of total RNA was labeled with biotin, and then it was
hybridized with locked nucleic acid (LNA)-modified capture probe
coupled with beads. After washing away the unbound RNA
samples, streptavidin-phycoerythrin (SAPE) reporter molecules
were added to the reaction and then the expression of miRNAs
was analyzed on Luminex analyzer.
Data analysis for miRNA profiling
A mock array was generated by averaging the expression of
each miRNA in all samples. Next, a linear correction for each
sample to the mock array was performed. The data were analyzed
using GenePattern software from Broad Institute. MiR-146b-5p
was deleted from the analysis due to abnormally high background
bead signals.
Gene set enrichment analysis
We defined a B cell miRNA activation signature as miRNAs
that were significantly altered with a t-test p-value of ,0.05 after
correction for multiple comparisons in control versus in vitro
activated B cells. We performed independent GSEA analysis for
upregulated and downregulated miRNA sets to test for enrichment
of activation signature miRNAs in control B cells versus CLL
profiles as described in [19].
MiRNA-specific RT-PCR assay
Total RNA was treated with DNase I (Ambion, Austin, TX,
USA), and cDNA synthesis was carried out using miScript Reverse
Transcriptase kit (Qiagen, Hilden, Germany). miRNA-specific RT-
PCRs were performed using the miScript primer assay according to
the manufacturer’s protocol (Qiagen, Hilden, Germany). The
miRNA specific primers and the internal control primers were
obtained from Qiagen (Hilden, Germany). The relative expression
of specific miRNAs was calculated by the DDCt method. A
randomly chosen subset of the CLL cell RNAs samples used for
Luminex bead-based miRNA expression profiling were used for
validation by RT-PCR-based miRNA expression profiling.
Statistical methods
Associations between miRNA expression and clinical charac-
teristics were assessed using the Fisher exact test for binary
MicroRNA in Chronic Lymphocytic Leukemia
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more categories. Time to first therapy was calculated as time from
initial diagnosis to first therapy; patients not yet treated were
censored at date last known alive. Time to first therapy was
estimated using the method of Kaplan and Meier; the log rank test
was used to assess associations with time to first therapy. Recursive
partitioning was used to identify an optimal binary split for each
miRNA individually, using the rpart package in R. P-values from
recursive partitioning are not adjusted for the optimization of the
method. Two-sided p-values are not adjusted to reflect multiple
comparisons; q-values reflect adjustment for multiple comparisons
using the false discovery rate of Benjamini and Hochberg, as
implemented in the q-value package in R. A false discovery rate of
0.10 or smaller was the criterion for reporting significant
differences in both clinical features and time to first therapy in
this study.
Results
Determinants of a CLL-specific miRNA expression
signature
CLL cells are characterized by expression of both CD5 and
CD19 cell surface markers [20]. CD19 bead positive selection was
used to purify CLL cells and greater than 97% CLL cell purity was
verified by FACS analysis of CD5 and CD19 expression for all
samples used in this study (Figure S1). We profiled miRNA
expression across 38 highly purified CLL patient samples, 9
control B cell samples and 5 activated B samples by CpG using the
Luminex method [18]. Unsupervised hierarchical analysis clus-
tered CLL samples based upon miRNA expression (Figure S2).
Comparative marker selective view alignment analysis in CLL
samples compared with control B samples identified a CLL-
specific miRNA signature consisting of upregulation of let-7g,
miR-26a, miR-29a, miR-29b, miR-29c, miR-101, miR-150, and
miR-155, and downregulation of miR-23a, miR-24, and miR-27b,
miR-181a, miR-181b, and miR-223 (Figure S3).
Though most B cells are CD5-CD19+, specific subsets of B cells
(e.g. peritoneal, tonsillar) are CD5+CD19+.T ov e r i f yt h a tm i R N A
expression profiling discerned differences between normal CD5-
CD19+ Bc e l l sa n dC D 5 +CD19+CLL cells rather than between
normal CD5-CD19+ and CD5+CD19+ Bc e l l s ,c o n t r o lBc e l l sf r o m
4 different control donors were sorted into CD5- and CD5+
populations and RT-PCR analysis was performed. Our data
indicate that miR-181a and miR-181b were downregulated in 6
CLL samples relative to both CD5- and CD5+ control B cell
populations. Similarly, miR-29a, miR-150, and miR-155 were
upregulated in CLL relative to both CD5- and CD5+ control B cell
populations (Figure S4). These data indicate that CD5+ expression
status does not affect the interpretation of the changes in miRNA
expression in these studies. Notably, CD19 positive purification does
not alter miRNA expression as assessed by RT-PCRs (Figure S5).
miRNA alterations identify an activated B cell phenotype
in CLL cells
Several characteristic miRNAs that have altered expression in
CLL relative to untransformed B cells are also important for
lymphocyte activation (e.g. miR-181a [21], miR-181b [22], miR-
150 [23], and miR-155 [24]), inflammatory responses (e.g. miR-
155 [25,26]), and B lymphoproliferative disorders (eg. miR-155
[27,28]). We thus hypothesized that CLL cells may derive from
partially activated B cells.
To systematically compare miRNA expression in CLL to the
miRNA changes induced by B cell activation, we identified sets of
miRNAs significantly (p,0.05) upregulated or downregulated after
untransformed B cell activation by CpG. The upregulated
miRNAs were miR-34a, miR-198, miR-155, miR-337-3p and
miR-342-3p and the downregulated miRNAs were let-7c, miR-
15b, miR-20b, miR-103, miR-181a, miR-181b, and miR-331-3p
(Figure 1A). We then performed GSEA for these upregulated and
downregulated miRNAs in CLL versus untransformed B cells
(Figure 1B and 1D). Four out of seven downregulated miRNAs
(miR-15b, miR-103, miR-181a, and miR-181b) were expressed at
lower levels in CLL, and five out of five upregulated miRNAs
(miR-34a, miR-155, miR-198, miR-337-3p and miR-342-3p) were
expressed at higher levels in CLL compared to untransformed B
cells (Figure 1C and 1E).
Next, we used miRNA-specific RT-PCR to confirm the
expression of these signature miRNAs in 3 control B samples
and 3 activated B samples (different from the samples used in the
miRNA profiling) after CpG activation (Figure 2A, 2B, and 2C)
and in control B samples and at least 4 CLL patient samples per
miRNA, (Figure 2D and 2E). Using RT-PCR, we independently
confirmed these miRNA expression patterns in control B and
activated B cells (Figure 2A and 2B). However, in CLL cells, miR-
337-3p demonstrated an opposite trend to the one identified in
GSEA of miRNA expression profiling (Figure 1E). Moreover,
miR-15b and miR-198 demonstrated a similar trend in as in
GSEA of miRNA expression profiling (Figure 1C and 1E) though
the p value was not statistically significant (Figure 2D and 2E).
Variations detected between Luminex bead-based profiling and
RT-PCR may be due to the heterogeneity of CLL as we used a
subset of CLL samples for the qPCR confirmation.
To mechanistically link altered miRNA expression in CLL with
altered expression of miRNAs observed in B cell activation, we
carefully examined the expression of one miRNA (miR-155) whose
expression is increased in CLL and in activated B cells. The miR-
155 gene is activated upon B cell stimulation and contains binding
sites for the AP-1 transcription factor. B cell activation stimulates
the JNK pathway, increases the levels of phospho-ERK, and then
activates AP-1 [29]. Treatment of CpG activated B cells and CLL
cells with either JNK or MEK inhibitor decreased the expression
of miR-155 (Figure S6A and S6B). These data indicate common
signaling pathways affect altered miRNA expression observed in
activated B cells and CLL cells.
To confirm the activation phenotype indicated by miRNA
expression profiling, we performed FACS analysis of naı ¨ve B cells,
activated B cells, and CLL cells using B cell activation markers
CD69, CD80, and CD86 (Figure 3 and Table S3). Our data
demonstrate that CLL cells express CD69 and CD80 at levels that
approximate the levels observed in activated B cells and that CLL
cells express CD86 at levels intermediate between naı ¨ve and
stimulated B cells. These data indicate that CLL cells have similar
gene expression patterns as activated B cells.
To independently verify that miRNA changes observed in CLL
cells are characteristic of an activated B cell status, we purified B
cells from healthy donors and stimulated these cells with a variety of
B cell activators including anti-IgM and CD40L (BCR and T cell-
assisted co-stimulatory pathways), and LPS, CpG, or polyI:C (Toll-
like receptor pathways) and examined miRNA expression.
Stimulation of highly purified, control B cells was verified by FACS
analysis of cell membrane expressed activation markers including
CD69, CD80 and CD86 expression (Figure 3 and Table S3).
In addition to the activation signature, additional miRNAs are
differently expressed in CLL compared to untransformed B cells.
We tested the expression patterns of these miRNAs to determine if
they also were altered in untransformed B cells upon activation.
For the CLL signature miRNAs, we found that activation of
control B cells led to reduced miR-23a, miR-23b, miR-24, miR-
MicroRNA in Chronic Lymphocytic Leukemia
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CLL signature) and increased miR-155 (upregulated in the CLL
signature), regardless of the mechanism of B cell activation (Figure
S7 and summarized in Table 1). Most miRNAs demonstrated
consistently altered expression regardless of the mechanism of B
cell activation though the expression of the miR-29 family varied
depending upon B cell activation. Whereas anti-IgM and CD40L
upregulated miR-29a (Figure S7A and S7B), LPS, CpG, or
polyI:C downregulated miR-29a (Figure S7C). In contrast, anti-
IgM and CD40L downregulated miR-29b and miR-29c (Figure
S7A and S7B) but LPS, CpG, or polyI:C upregulated miR-29b
and miR-29c (Figure S7C). miR-223 is increased in response to
CD40L activation (Figure S7B), while decreased in response to all
other stimuli (Figure S7A and S7C). Additionally, the expression of
miR-26a was increased in CLL and only in B cells activated with
CD40L but did not change in B cells activated with anti-IgM
(Figure S7A and S7B). These data suggest that particular CLL
signature miRNAs are altered in response to specific B cell stimuli.
In contrast, miR-150 was reduced during B cell activation, and
upregulated in almost all the CLL samples tested (Table 1). Thus,
high expression of miR-150 may be CLL specific.
Signature miRNA alterations are associated with clinical
features and time to first therapy
Previous reports suggest that altered miRNA expression has
prognostic value [30,31,32]. ZAP70 and IgVH mutational status
are strongly associated with clinical outcome for CLL patients.
Thus, comparative marker alignments were performed to identify
miRNAs clustered by ZAP70 and IgVH status (Table S4A and
S4B). Out of 38 patients, we examined 14 ZAP70
+ patients and 14
IgVH unmutated patients (Table S1). We found that miR-150 was
upregulated in ZAP70
+ patients whereas miR-29c and miR-223
were upregulated in both ZAP70
2 and in IgVH mutated patients
suggesting that decreased levels of miR-150 and increased levels of
miR-29c and miR-223 may be associated with better clinical
outcomes. Our data do not indicate a statistically-significant
correlation between miR-29c and miR-223 with any established
cytogenetic abnormalities used to distinguish CLL patient sub-
populations, such as 17p, 11q and 13q deletion and trisomy 12
(data not shown). Additionally, miR-92a was upregulated in
ZAP70
2 patients and let-7g was upregulated in IgVH mutated
patients (Table S4A and S4B).
We also examined miRNA expression across CLL cells for
association with time to first therapy in these patients. Using
recursive partitioning analysis for finding optimal cut points for
miRNA expression, we examined time to first therapy. We
identified two miRNAs (miR-29c and miR-223) with q-values of
0.07 associated with an optimized binarysplit (Kaplan-Meiercurves
and the optimal splits are indicated (Figure 4)). CLL patients with
lower expression levels of these miRNAs demonstrated shorter time
to first therapy compared to CLL patients who did not demonstrate
this pattern of miRNA expression. Decreased expression of these
Figure 1. GSEA reveals a B cell activation miRNA signature in CLL. A. Heatmap of B cell activation signature miRNAs comparing expression in
unstimulated control B (CB) cells and CpG activated B cells (CB act). B. GSEA enrichment profile of downregulated B cell activation signature miRNAs
in control B cells versus CLL cells. C. Heatmap of downregulated B cell activation signature miRNA expression in control B cells and CLL cells. D. GSEA
enrichment profile of upregulated B cell activation signature miRNAs in control B cells versus CLL cells. E. Heatmap of upregulated B cell activation
signature miRNA expression in control B cells and CLL cells.
doi:10.1371/journal.pone.0016956.g001
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+ and IgVH
unmutated patients (Table S4A and S4B) implying poor prognosis.
Discussion
miRNA expression profiling has been used to identify signatures
that classify CLL [10,11,12,33]. Interestingly, none of these
published signatures are identical (Table S5). The reasons for the
different miRNA signatures are unknown. Different methods and
different miRNA analysis platforms may partly explain the
different signatures identified by each of these groups. Calin et
al. profiled 94 CLL patient samples using a miRNA microarray
but did not purify CLL cells to homogeneity [10,11]. Fulci et al.
profiled 56 CLL patient samples by cloning and SYBR-green-
based RT-PCR [12]. Zanette et al. profiled miRNA expression in
9 CLL patients and 6 healthy donors using TaqMan-based
miRNA assays [13]. However, CLL is a heterogeneous disease and
it is possible that different patient populations have unique
miRNA expression patterns. Interestingly, Zhang et. al. [14]
demonstrated CLL cells are more like memory B cells based on
miRNA profiling, our miRNA profiling data showed CLL cells are
behaving like activated B cells at an earlier time point.
The uniformity of miRNA expression changes in CLL patient
samples relative to B cells is striking (Figure 1 and Figure S3).
Though the directionality of changes in expression is consistent for
these particular miRNAs, the magnitude of changes varies
considerably for these particular miRNAs. Indeed, some miRNAs
demonstrate expression variance over several orders of magnitude.
Figure 2. Validation of altered miRNA expression identified by GSEA. miRNA-specific RT-PCR independently confirms altered expression of
GSEA-identified miRNAs in B cells activated with CpG. A. miR-181a, miR-181b, miR-20b, miR-103, miR-15b, miR-331-3p, and let-7c. B. miR-155. C. miR-
342-3p, miR-337-3p, miR-198, and miR-34a. For (A, B, C), B (-): control B cell samples. B (+): corresponding activated B samples by CpG. Error bars
indicate the standard deviation of 3 independent samples. D, E. miRNA-specific RT-PCR confirms the differential expression of subsets of GSEA-
identified miRNAs in CLL relative to control B cells. Upregulated miRNAs are miR-34a, miR-155, miR-198 and miR-342-3p. Downregulated miRNA
expression including let-7c, miR-15b, miR-20b, miR-103, miR-181a, miR-181b, miR-331-3p and miR-337-3p. Between 4 to 8 control unstimulated B cell
samples (square) and between 6 to 21 CLL patient samples (triangle) were used. The bar indicates the average expression in each group. p-value for
the analysis calculated by t-test is shown. miRNA expression was normalized by snoRNA-RNU44 expression. Relative miRNA expression was calculated
by DDCt method and is indicated on the Y-axis.
doi:10.1371/journal.pone.0016956.g002
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the heterogeneous clinical course. Notably, nine of the 12 miRNAs
changed in the same direction in CLL cells compared to their
changes when B cells are activated (Figure 1). Several factors can
affect the direction of miRNA expression changes in CLL cells and
activated B cells including the timing of altered miRNA
expression, type of stimulation, or that certain changes may be
important to the pathobiology of CLL. Interestingly, the
expression of the two prognostic miRNAs (miR-29C and miR-
223) varies in activated B cells depending upon the type of
stimulation (Table 1). Interrogating the causes and consequences
of altered miRNA expression in CLL cells in common with and
distinct from altered miRNA expression in activated B cells will
improve our understanding of this disease.
Another striking finding is that certain CLL signature miRNAs
demonstrate similar trends in activated B cells regardless of the
mechanism of activation (Table 1). Mir-23a, miR-23b, miR-24, miR-
27b, miR-155, miR-181a, miR-181b, and miR-223 are all altered
consistently with activated B cells. However, certain CLL signature
miRNAs are altered consistent with specific B cell activators. For
example miR-29b and miR-29c are downregulated with IgM and
CD40L activation but are upregulated with TLR activation. Two
recent reports examine differential miRNA expression in naı ¨ve,
germinal center, memory and plasma B cell populations [14,34].
Interestingly, miR-29c is reduced in germinal center B cells [14] and
in centroblasts [34] but is increased in memory B cells [14]. The
pattern of miR-29 family member expression may be affected by the
duration of B cell activation and/or to multiple B cell activators
present in germinal centers proceed through T cell-dependent (e.g.
CD40L) and T cell-independent (e.g. anti-IgM) pathways acting
simultaneously. Still, certain alterations in miRNA expression are
common with published observations such as downregulated miR-
181b and miR-223 [34] regardless of the mechanism of activation
suggesting that B cell activation may converge on common miRNA-
regulated pathways. Importantly, these common miRNAs are also
present in the CLL signature reported here.
Recent reports indicate that certain miRNAs identified in this
CLL signature have prognostic value in CLL [30,31,32]
Additionally, CLL patients expressing CD38 tend to have higher
expression of activated cellular markers, including CD27, CD62L,
CD69 and KI-67, and this activation status is correlated with poor
clinical outcomes [35,36]. Our study integrates these two
Figure 3. CLL cells express elevated levels of B cell activation markers. Unstimulated donor B cells, anti-IgM-activated donor B cells, or CLL
cells were stained for CD69, CD80 or CD86 levels by FACS analysis. Grey filled curve shows the isotype control, open curve shows the specific
antibody staining. One representative unactivated donor B cell sample (B-), one anti-IgM-activated B cell sample (B+) and two CLL samples (L30 and
L41) are shown. An expanded analysis of donor and patient samples is shown in Table S3.
doi:10.1371/journal.pone.0016956.g003
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outcomes are a part of a larger pattern of miRNA changes
consistent with B cell activation. In B cells, miR-29c and miR-223
are both reduced after BCR or co-stimulatory activation. In CLL
cells, decreased miR-29c and miR-223 are associated with
ZAP70
+ and IgVH unmutated status (Tables S4A and S4B) and
shorter times to first therapy (Figure 4).
We do not have access to sufficient number of fresh samples
from additional patients with full clinical annotation to serve as a
validation set for these observations. However, these observations
are consistent with previous observations that have associated
reduced levels of these two miRNAs with ZAP70
+ and IgVH
unmutated status [11,12,32,37]. Moreover, previous studies have
associated reduced miR-29c with p53 status and 17p deletion, the
worst prognostic group in CLL [30,31]. We did not identify an
association between reduced miR-29c and any cytogenetic
abnormalities (data not shown). miR-29c and miR-223 co-vary
with other clinical parameters and thus may not have independent
prognostic value, but these miRNA changes may have biological
function in CLL. For example, reduced levels of miR-29c have
been shown to de-repress expression of MCL-1 and TCL-1,
known oncogenes implicated in the CLL anti-apoptotic defect
[30,31,33]. BCR activation led to downregulation of miR-29c and
miR-223 (Figure S7A) and ZAP70 is associated with increased
BCR signaling in CLL [38]. It is likely that miR-29c and miR-223
are negatively affected by enhanced BCR signaling mediated by
ZAP70 [38]. Although the kinase domain of ZAP70 is not
required for BCR pathway stimulation in CLL, the scaffolding
function of ZAP70 acts as an adaptor that clusters and thereby
increases signaling through BCRs in CLL [38,39]. Thus,
downregulation of miR-29c and miR-223 may potentiate BCR
signaling and accelerate CLL oncogenesis.
Other miRNA changes consistent with B cell activation may
also have an important role in CLL oncogenesis. miR-155
demonstrates an average of 50-fold increase in expression in
CLL cells tested compared with control B cells (Figure 2D), is
increased in multiple cancers [27,28,40], and promotes B cell
lymphomagenesis [41]. Conversely, miR-181a and miR-181b
demonstrate approximately a 100-fold decrease in expression in
virtually all CLL cells tested as compared with control B cells
(Figure 2E). PI-3K is a predicted target of miR-181a and miR-
181b [42] and the PI3K pathway has been implicated in the
apoptotic defect in CLL cells [43]. These data suggest that miR-
155 has an oncogenic function whereas miR-181a and miR-181b
have a tumor suppressive function in CLL. Analysis of changes in
miRNA expression and their target genes during B cell activation
and CLL oncogenesis will provide insights into the physiological
roles of these miRNAs. Understanding the roles of miRNAs in the
dysregulated gene networks that underlie the pathology of CLL
could enable the application of miRNA-based therapeutics for this
common leukemia.
Table 1. Signature miRNA expression comparison between
activated B cells and CLL cells relative to control B cells.
miRNA list Activation CLL
IgM/CD40L TLRs
let-7g
miR-23a
miR-23b
miR-24
miR-26a -/
miR-27b
miR-29a
miR-29b
miR-29c
miR-101
miR-150
miR-155
miR-181a
miR-181b
miR-223
Up and down arrows indicate upregulation or downregulation of specific
miRNAs, respectively, when compared to untransformed, control B cells. A
parallel line indicates no change when compared to untransformed, control B
cells. miR-223, miR-29a, miR-29b and miR-29c are upregulated in response to
certain B cell activators and downregulated in response to other B cell
activators. miR-26a is unaffected by IgM stimulation, but upregulated in
response to other B cell activators.
doi:10.1371/journal.pone.0016956.t001
Figure 4. The expression of miR-29c and miR-233 is associated with time to first therapy in CLL. A shorter time from diagnosis to
initiation of first therapy is significantly associated with reduced expression of miR-29c and miR-223. A recursive partitioning approach identifies the
optimal split for each miRNA: miR-29c expression at 11.82 or lower is associated with shorter time to first therapy, q=0.07. miR-223 expression at a
level of 11.14 or lower is associated with shorter time to first therapy, q=0.07.
doi:10.1371/journal.pone.0016956.g004
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Figure S1 Purity of CLL sample after CD19 positive
selection. FACS analysis was performed on PBMCs (PBMC) and
purified CLL cells (CLL) using anti-human CD19 and anti-human
CD5 antibodies. The purity of the CLL cells was shown as the
percentage number on the CD5+CD19+population.
(TIF)
Figure S2 Hierarchical clustering of miRNAs expressed
in CLL, control B cell, and activated B cells. Heatmap of
miRNA expression across 38 patient-derived CLL samples, 9
donor B cell samples, and 6 CpG activated donor B cell samples.
miRNA expression is hierarchically clustered on the Y-axis and
patient-derived CLL samples or control B cell donors are
hierarchically clustered on the X-axis. The relative expression of
miRNAs is depicted according to the color scale shown on the
right. CB#: donor control B sample; CB# act: donor activated B
samples by CpG; L#: CLL samples.
(TIF)
Figure S3 Comparative marker selective view align-
ment miRNA expression distinguishes miRNA expres-
sion between unactivated donor B cells from CLL cells.
Comparative marker selective view alignment distinguishes
upregulated miRNA expression in 9 control, unactivated B cell
sample (Y-axis, red) and in 38 CLL cell patient samples (X-axis,
blue). Score (Y-axis) refers to the t-test score indicating the metric
correlating gene expression and phenotype. The calculation of t-
test score is: (m1–m2)/ (s1‘2+s2‘2)‘0.5, where m1 is the mean of
class 1 and m2 is the mean of class 2, and s1 and s2 are the
standard deviation of class 1 and 2. A high score indicates
association with the first phenotype (upregulated in control B cells)
and a low score indicates association with the second phenotype
(upregulated in CLL cells). False Discovery Rate (FDR) is 0.004
for all the miRNAs shown in the diagram.
(TIF)
Figure S4 miRNA expression profiling in CD5+B cells in
comparison to CD5- B cells. B cells were isolated from four
donors and six CLL patient samples by CD19+selection. Control
B cells were stained with anti-human CD5 and CD19 antibodies,
FACS sorted for CD5-CD19+(CD5-) and CD5+CD19+(CD5+)B
cells and miRNA expression was analyzed by RT-PCR. Relative
expression of miRNAs in CD5- (square), CD5+control B cells
(diamond) and CLL samples (triangle) was normalized to RNU44.
Each bar indicates the average expression in each group. p value of
the analysis calculated by t-test is shown.
(TIF)
Figure S5 Signature miRNA expression is not signifi-
cantly altered in CLL cells before and after CD19
positive selection. Total RNA extracted from PBMC or
purified CD19+CLL cells from three CLL patient samples with
high white blood cell counts (.50610
3/mL blood) (CLL) were
analyzed by miRNA-specific RT-PCR. The relative expression of
miR-26a, miR-29a, miR-29b, miR-150, miR-155, miR-181a,
miR-181b, and miR-223 are shown.
(TIF)
Figure S6 Inhibition of miR-155 expression by MEK and
JNK inhibitors. A. Relative expression of miR-155 in CLL cells
treated with MEK (PD98059; PD) and JNK (SP600125; SP)
inhibitors. B. Relative expression of miR-155 in CpG-activated B
cell treated with PD98059 and SP600125 inhibitors. Cells were
cultured with DMSO as a control (DMSO).
(TIF)
Figure S7 miRNA expression distinguishes unstimu-
lated B cells from activated B cells. A. anti-IgM was used to
activate B cells for 24 or 48 hrs and miRNA-specific RT-PCRs
was performed on control B cells before and after activation. B.
The same analysis as in (A) by CD40L for 24 hr or 48 hrs. Co-
culturing with the 3T3 feeder cells as the control. C. The same
analysis as in (A) after LPS, CpG or poly(I:C) activation for 24 hr
or 48 hrs. Error bars indicate the standard deviation of duplicates.
(TIF)
Table S1 Summary of clinical parameters of CLL
patients samples used in these studies.
(DOC)
Table S2 miRNAs tested in FlexmiR v2 expression
profiling.
(DOC)
Table S3 Cell surface marker expression is compared
among unactivated donor B cells, anti-IgM-activated
donor B cells, and CLL cells. FACS analysis was performed
using FITC-labeled different surface marker antibodies. 16
different CLL samples (L#), 5 donor control B cell samples (CB)
and 3 activated B cell samples by anti-IgM F(ab’)2 are shown.
(DOC)
Table S4 miRNAs correlated with ZAP70 and IgVH
status. Wilcoxon rank sum tests were used for whether there
were any differences on miRNA expression pattern between
patients with different clinical features such as (S4A) ZAP70 status,
and (S4B) IgVH status. p-value and q-value for each miRNA are
shown. N: patient number.
(DOC)
Table S5 CLL-specific miRNA signatures identified by
different groups.
(DOC)
Methods S1
(DOC)
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